CHARM Therapeutics uses deep learning on 3D molecular configurations to develop molecule therapeutics to target pathogenic proteins.
Theolytics
Series A • Oxford, United Kingdom
Sano Genetics
Series A • England, United Kingdom
Chroma Medicine
Series A • Cambridge, United States
CytoKi Pharma
Series A • Værløse, Denmark
Elwood
Series A • London, United Kingdom
Storm4
Series A • London, United Kingdom
Peppy
Series A • London, United Kingdom
Qkine
Seed • Cambridge, United Kingdom
Xontogeny
Series A • Boston, United States
Gameto
Series A • New York, United States
Edinburgh Molecular Imaging
Non Equity Assistance • Scotland, United Kingdom
STORM Therapeutics
Grant • Babraham, United Kingdom